292 related articles for article (PubMed ID: 35710296)
1. Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma.
Ramamoorthi G; Kodumudi K; Snyder C; Grover P; Zhang H; Greene MI; Basu A; Gallen C; Wiener D; Costa RLB; Han HS; Koski G; Czerniecki BJ
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35710296
[TBL] [Abstract][Full Text] [Related]
2. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
Kodumudi KN; Ramamoorthi G; Snyder C; Basu A; Jia Y; Awshah S; Beyer AP; Wiener D; Lam L; Zhang H; Greene MI; Costa RLB; Czerniecki BJ
Front Immunol; 2019; 10():1939. PubMed ID: 31475002
[TBL] [Abstract][Full Text] [Related]
3. Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.
Datta J; Berk E; Xu S; Fitzpatrick E; Rosemblit C; Lowenfeld L; Goodman N; Lewis DA; Zhang PJ; Fisher C; Roses RE; DeMichele A; Czerniecki BJ
Breast Cancer Res; 2015 May; 17(1):71. PubMed ID: 25997452
[TBL] [Abstract][Full Text] [Related]
4. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
[TBL] [Abstract][Full Text] [Related]
5. Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.
Muraro E; Comaro E; Talamini R; Turchet E; Miolo G; Scalone S; Militello L; Lombardi D; Spazzapan S; Perin T; Massarut S; Crivellari D; Dolcetti R; Martorelli D
J Transl Med; 2015 Jun; 13():204. PubMed ID: 26116238
[TBL] [Abstract][Full Text] [Related]
6. Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells.
Mortenson ED; Park S; Jiang Z; Wang S; Fu YX
Clin Cancer Res; 2013 Mar; 19(6):1476-86. PubMed ID: 23363817
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the combination of anti-PD-L1 mAb with HER2/neu-loaded dendritic cells and QS-21 saponin adjuvant: effect against HER2 positive breast cancer in mice.
Özverel CS; Uyanikgil Y; Karaboz İ; Nalbantsoy A
Immunopharmacol Immunotoxicol; 2020 Aug; 42(4):346-357. PubMed ID: 32515626
[TBL] [Abstract][Full Text] [Related]
8. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
[TBL] [Abstract][Full Text] [Related]
9. CD4(+) T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8(+) T-cell Targeting of HER2/neu-Expressing Cancers.
Datta J; Xu S; Rosemblit C; Smith JB; Cintolo JA; Powell DJ; Czerniecki BJ
Cancer Immunol Res; 2015 May; 3(5):455-63. PubMed ID: 25791067
[TBL] [Abstract][Full Text] [Related]
10. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
11. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
12. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
13. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
[TBL] [Abstract][Full Text] [Related]
14. Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2
Lowenfeld L; Mick R; Datta J; Xu S; Fitzpatrick E; Fisher CS; Fox KR; DeMichele A; Zhang PJ; Weinstein SP; Roses RE; Czerniecki BJ
Clin Cancer Res; 2017 Jun; 23(12):2961-2971. PubMed ID: 27965306
[No Abstract] [Full Text] [Related]
15. Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors.
Triulzi C; Vertuani S; Curcio C; Antognoli A; Seibt J; Akusjärvi G; Wei WZ; Cavallo F; Kiessling R
Cancer Res; 2010 Oct; 70(19):7431-41. PubMed ID: 20823150
[TBL] [Abstract][Full Text] [Related]
16. Vaccine-Induced Memory CD8
Crosby EJ; Gwin W; Blackwell K; Marcom PK; Chang S; Maecker HT; Broadwater G; Hyslop T; Kim S; Rogatko A; Lubkov V; Snyder JC; Osada T; Hobeika AC; Morse MA; Lyerly HK; Hartman ZC
Clin Cancer Res; 2019 May; 25(9):2725-2736. PubMed ID: 30635338
[TBL] [Abstract][Full Text] [Related]
17. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
Homma S; Komita H; Sagawa Y; Ohno T; Toda G
Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
[TBL] [Abstract][Full Text] [Related]
18. Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKT lymphocytes.
Margalit M; Shibolet O; Klein A; Elinav E; Alper R; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2005 Jun; 115(3):443-9. PubMed ID: 15688366
[TBL] [Abstract][Full Text] [Related]
19. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
[TBL] [Abstract][Full Text] [Related]
20. Anti-HER2 CD4
De La Cruz LM; McDonald ES; Mick R; Datta J; Nocera NF; Xu S; Fisher CS; Czerniecki BJ
Ann Surg Oncol; 2017 Apr; 24(4):1057-1063. PubMed ID: 27826664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
